insights_auto
Why is INO down 2,76%?
Dive Deeperchevron_right
INO:NASDAQ
Inovio Pharmaceuticals Inc
1,58 US$
arrow_downward
-2,76%(-0,045) 1D
18 ნოე, 11:25:05 GMT-5 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for INO...
Open
1,64 US$
High
1,66 US$
Low
1,56 US$
Mkt. cap
296,88 მლნ.
Avg. vol.
19,92 მლნ.
Volume
4,05 მლნ.
52-wk high
2,72 US$
52-wk low
0,57 US$
EPS
-0,80 US$
Beta
1,71
Shares outstanding
187,31 მლნ.
No. of employees
112
Open
1,64 US$
High
1,66 US$
Low
1,56 US$
Mkt. cap
296,88 მლნ.
Avg. vol.
19,92 მლნ.
Volume
4,05 მლნ.
52-wk high
2,72 US$
52-wk low
0,57 US$
EPS
-0,80 US$
Beta
1,71
Shares outstanding
187,31 მლნ.
No. of employees
112
News stories
From web sources and news partners
Investing.com
·
2 საათის წინ
Inovio submits European approval application for RRP treatment
Yahoo Finance
·
13 საათის წინ
Inovio Pharmaceuticals (INO) Stock Gets Fair Value Boost After VOCERYQ Approval
The Business Journals
·
1 დღის წინ
After 43 years, Inovio gets its first FDA-approved drug in 'milestone' decision
Profile
Inovio Pharmaceuticals, Inc. is an American biotechnology company focused on the discovery, development, and commercialization of synthetic DNA products for treating cancers and infectious diseases. In April 2020, Inovio was among some 100 companies, academic centers, or research organizations developing a vaccine candidate for treating people infected with COVID-19, with more than 170 total vaccine candidates in development. Wikipedia
About Inovio Pharmaceuticals Inc